GlobalData Healthcare

All articles by GlobalData Healthcare

1. Parkinson’s gene therapy development to restart in summer 2019

   Development of the Parkinson’s disease gene therapy that UniQure was previously involved in will be restarted in a Phase II trial this…
   Read More…

   19 Apr
2. Minerva to explore therapy in treatment-naïve schizophrenia and more

   Minerva Neurosciences’ MIN-101 (roluperidone) is being considered for a future trial in treatment-naïve schizophrenia patients and additional indications with apathy symptoms,…
   Read More…

   19 Apr
3. ViiV adds another innovative treatment to its growing HIV arsenal

   On April 8, ViiV Healthcare announced that the FDA has approved Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus…
   Read More…

   18 Apr
4. NDAs submitted to the FDA for the first oral GLP-1 receptor agonist

   Last month Novo Nordisk submitted two new drug applications (NDAs) to the FDA for its glucagon-like peptide-1 receptor agonist (GLP-1RA),…
   Read More…

   18 Apr
5. HIPAA-compliant Alexa skills: a new opportunity for pharma

   Earlier this month, Amazon announced that the Alexa Skills Kit now enables companies that are HIPAA-compliant (subject to the US…
   Read More…

   18 Apr
6. NIH strategy shows promise in hunt for universal influenza vaccine

   On April 3, the US National Institutes of Health (NIH) announced the start of a Phase I clinical trial investigating…
   Read More…

   16 Apr
7. Excellent phase 3 trial data for rheumatoid arthritis drug filgotinib – but long road ahead

   On 28 March 2019, Gilead and Galapagos announced that their selective JAK1 inhibitor, rheumatoid arthritis (RA) drug filgotinib , had…
   Read More…

   16 Apr
8. Positive findings from Amarin’s REDUCE-IT trial bode well for important Vascepa label expansion

   On 18 March, Amarin presented new positive data from its landmark cardiovascular (CV) outcomes study of its prescription fish oil…
   Read More…

   8 Apr
9. JC Pharma plans stock exchange listing to develop CannatolRx

   JC Pharma is in talks with a Toronto firm to list on the Toronto stock exchange (TSXE), so it can…
   Read More…

   5 Apr
10. Roche’s Tecentriq/Avastin to be trialled in lung cancer study without chemotherapy

    Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) will be evaluated in an investigator-led Phase II non-small-cell lung cancer (NSCLC) trial as…
    Read More…

    5 Apr